Evaluating the efficacy of tissue-engineered human amniotic membrane in the treatment of myocardial infarction.

CONCLUSION: Histological and immunohistochemical evaluations indicated the regeneration of cardiomyocytes and reduction of inflammation and fibrosis in the patch-implanted group compared with a control group, 14 days after the surgery. Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate biotin nick-end labeling assay was suggestive for apoptosis reduction in the patch-implanted specimens. This study suggested that human AM can be developed into a novel treatment for treating postmyocardial infarction. PMID: 30741604 [PubMed - as supplied by publisher]
Source: Regenerative Medicine - Category: Genetics & Stem Cells Authors: Tags: Regen Med Source Type: research